JAK2 V617F: How One Mutation Became a Major Criterion for Polycythemia Vera

A single acquired mutation, JAK2 V617F, sits in more than 95 percent of polycythemia vera cases, which is why the World Health Organization ranks it as a major diagnostic criterion. Its rarity in healthy people gives a positive result strong weight when a patient turns up with a stubbornly high red cell count. A negative test, though, does not close the question. A smaller group carries a different JAK2 change in exon 12, and a rare few carry neither.

What the mutation actually does

JAK2 is a signaling enzyme that sits just inside blood-forming cells and relays growth messages from receptors, including the erythropoietin receptor that governs red cell production. The V617F mutation swaps a single amino acid (valine for phenylalanine at position 617) in a regulatory region that normally keeps the enzyme quiet until a signal arrives. The altered enzyme fires without waiting for that signal. The marrow behaves as though it is being told to make red cells around the clock, even when erythropoietin levels are low. That mismatch, high red cell mass alongside a suppressed erythropoietin level, is the biological signature of polycythemia vera.

Because the mutation is acquired in blood-forming cells rather than inherited, it marks the disease as a clonal process: one rogue stem cell and its descendants outcompeting normal marrow. That clonality is the concept the diagnostic criteria are built to capture.

Why it earned major-criterion status

Diagnostic tests earn their weight from two numbers pulling in opposite directions: how often the marker shows up in people who have the disease, and how rarely it shows up in people who do not. JAK2 V617F scores well on both. It appears in the large majority of confirmed polycythemia vera cases, and it is uncommon in the general population without a myeloproliferative neoplasm.

The 2022 WHO classification lists three major criteria for polycythemia vera: elevated hemoglobin, hematocrit, or red cell mass; bone marrow biopsy showing the characteristic overgrowth of all three cell lines; and the presence of a JAK2 V617F or JAK2 exon 12 mutation. A low serum erythropoietin level serves as a minor criterion. Diagnosis generally rests on all three major criteria, or the first two plus the minor one. Placing the mutation among the majors reflects a practical judgment: in someone with a genuinely high red cell mass, a positive JAK2 result points hard toward a primary marrow disorder rather than a secondary cause such as low oxygen, sleep apnea, or excess erythropoietin from another source.

That shift showed up in real practice. A 2014 analysis in Annals of Hematology, reviewing how the JAK2V617F test was used in a diagnostic scheme, found that a sizable share of mutation-positive patients were labeled with polycythemia vera on molecular grounds without a supporting erythropoietin level or bone marrow study. The test had become a shortcut. The same paper is a caution as much as an endorsement, because a shortcut can skip the very findings that confirm the picture.

The exon 12 group, and why the criterion names it

A positive JAK2 test is not always the V617F variant. In 2007, a New England Journal of Medicine report described a distinct set of gain-of-function mutations in JAK2 exon 12, found in patients who tested negative for V617F. These patients often presented with isolated erythrocytosis, a somewhat different marrow appearance, and low erythropoietin. Exon 12 mutations are uncommon overall, accounting for a low single-digit percentage of polycythemia vera, but among the V617F-negative subset they explain a large fraction of cases.

That is why the WHO criterion reads V617F or exon 12. Naming both closes a gap that a V617F-only test would leave open. It also carries a lab-ordering consequence: a first-line V617F assay that comes back negative in someone with a convincing high red cell mass and a low erythropoietin should prompt reflex testing for exon 12 rather than a stop.

What a negative test does and does not settle

A negative result is where the reasoning gets careful. The predictive value of any test depends on how likely the disease was before the test was run. In a person whose high hematocrit is fully explained by dehydration, smoking, or altitude, a negative JAK2 result mostly confirms a low starting suspicion. In a person with a truly elevated red cell mass and a suppressed erythropoietin, the same negative result carries a different weight, because a small number of genuine cases sit outside both known JAK2 hotspots.

The 2008 study in the American Journal of Medical Sciences, examining how V617F testing was used and how often it changed a diagnosis in an academic practice, illustrates the modest but real value of the test in clarifying uncertain cases rather than replacing the rest of the workup. A negative test does not, by itself, rule out polycythemia vera when the clinical and laboratory picture still points that way. That is when the other major criteria, particularly the bone marrow biopsy, do the work the molecular test could not.

This article is educational and not medical advice; decisions about testing and diagnosis belong with a qualified clinician who can weigh the whole picture. The larger lesson generalizes past this one disease. A marker earns major-criterion status through high prevalence in the affected and rarity in the unaffected, and even a strong marker is read against the pretest odds rather than in isolation. JAK2 V617F is close to a textbook example of a molecular finding that reshaped a diagnostic scheme, and also a reminder that a single test, however good, is one line in a longer case.